Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has completed a voluntary public tender offer for shares in Vietnam’s Imexpharm Corporation through its subsidiary LIANSGP Holding Pte. Ltd., after the offer period closed on 29 April 2026. Shareholders of Imexpharm tendered 104,545,781 shares at VND57,400 per share, below the original upper limit of 120,059,970 shares targeted in the bid.
Following confirmation from the Vietnam Securities Depository and Clearing Corporation’s Ho Chi Minh City branch, the transfer of these shares has been finalized, giving Livzon an effective holding of 67.87% of Imexpharm’s registered capital and 67.88% of its voting shares. The acquisition secures Livzon a controlling stake in the Vietnamese listed drugmaker, strengthening its strategic foothold in Vietnam’s pharmaceutical market and consolidating its regional expansion efforts.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company listed in Hong Kong, focused on the research, development, production and sale of medicines and related healthcare products. The group is expanding its presence in overseas markets, including Southeast Asia, as part of its broader growth and internationalization strategy.
YTD Price Performance: -2.81%
Average Trading Volume: 873,239
Technical Sentiment Signal: Hold
Current Market Cap: HK$29.99B
See more data about 1513 stock on TipRanks’ Stock Analysis page.